Di Domenicantonio R, et al. - Experts performed this population-based cohort study to compare the risk of abdominal surgery, steroid utilization, and hospitalization for infection in Crohn’s disease (CD) or ulcerative colitis (UC) patients newly treated with infliximab (IFX) or adalimumab (ADA). No variation was reported with regard to the effectiveness and safety data in patients treated with ADA and those treated with IFX for CD or UC.